Era7295N7W | 759425-28-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Era7295N7W
• 英文别名: 3-hexoxy-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole
• CAS: 759425-28-0
• 化学式: C14H20N3OS+
• 分子量: 278.4
• InChiKey: NLBRMIWFUVXSRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67.1
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation
  申请人：Karuna Therapeutics, Inc.

  公开号：US10925832B2

  公开（公告）日：2021-02-23

  Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

  本文提供了一种口服药物组合物，该组合物由多个沙诺美林珠子和多个曲松珠子组成，前者的核心由沙诺美林或其盐组成；后者的核心由曲松盐组成。
• Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
  申请人：Karuna Therapeutics, Inc.

  公开号：US10933020B2

  公开（公告）日：2021-03-02

  Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof, and a plurality of trospium beads having a core comprising a salt of trospium.

  本文提供了一种口服药物组合物，该组合物包括多个以沙诺美林或其盐为核心的沙诺美林珠和多个以曲铵盐为核心的曲铵盐珠。
• COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
  申请人：Karuna Therapeutics, Inc.

  公开号：US20200101018A1

  公开（公告）日：2020-04-02

  Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.